Navigation Links
The Rottenstein Law Group LLP Notes Lifelong Side Effects of DES Can Lead to Cancer
Date:5/31/2013

(PRWEB) May 31, 2013

Diethylstilbestrol (DES), a synthetic hormone previously manufactured by several companies and formerly prescribed to pregnant women to prevent miscarriages and premature births, could potentially cause cancer in those women’s children. The Rottenstein Law Group LLP acknowledges a Centers for Disease Control report of the struggles of "DES Daughters" with a series of life-threatening cancers related to their mother’s use of the drug while pregnant. The firm maintains a DES Cancer Lawsuit Center at http://www.descancerlawsuit.com that features more details about lawsuits and the side effects of the drug.

The CDC report* notes ongoing research into the manifestation of "clear cell adenocarcinoma, structural abnormalities in the reproductive organs, infertility and pregnancy complications."

Rottenstein Law Group LLP Principal Rochelle Rottenstein comments on the research and how it relates to the communication she has received from those looking to file DES lawsuits.

“The first DES cancer lawsuits began as far back as the 1970s, but recently there have been more suits filed because of the drug’s serious alleged lifelong side effects,” Rottenstein said. “Some side effects don’t show up until later in the lives of so-called DES children and grandchildren.”

DES was prescribed to more than 10 million women from the 1940s to the 1970s to prevent miscarriages and premature births. Use of the drug by pregnant mothers allegedly led to their children experiencing cancer, infertility, and pregnancy difficulties, according to the National Cancer Institute.**

In 2013 about 51 women have filed suits in Boston against a dozen manufacturers or marketers of the drug, according to the Associated Press.*** One lawsuit was settled in January 2013 after a day at trial (1:11-cv-10152-MBB in the U.S. District Court for the District of Massachusetts).

The Rottenstein Law Group LLP encourages those who believe they have suffered DES side effects to visit its page dedicated to providing information about the DES link to certain types of cancers reportedly related to a pregnant woman’s use of the drug.

*cdc.gov/des/consumers/about/concerns_daughters.html
**cancer.gov/cancertopics/factsheet/Risk/DES
***sentinelandenterprise.com/breakingnews/ci_22341598/ap-settlement-reached-mass-lawsuit-pregnancy-drug (January 2013)

For the latest news on defective medications and medical devices and related lawsuits, visit the Rottenstein Law Group LLP’s Injury Lawyer Newswire at injurylawyernewswire.com. Readers can subscribe to the news site’s stories and videos to stay on top of personal injury news.

About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com

                            ###

Read the full story at http://www.prweb.com/releases/des-lawsuit/des-cancer/prweb10786743.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. FDA Says Metal-on-Metal Hip Replacements Can Cause Soft-Tissue Damage, Rottenstein Law Group Reports
2. Stryker Hip Replacement Lawsuit News: Mass. Woman Files First Known Federal Stryker ABG II Hip Lawsuit, Rottenstein Law Group Reports
3. DePuy ASR Lawsuit Update: Rottenstein Law Group Addresses J&J Motion to Appeal $8.3 Million Verdict
4. Fosamax Lawsuits Update: Rottenstein Law Group Responds to Femur Fracture Verdict in Merck’s Favor
5. Da Vinci Surgical Robot Lawsuit News: Rottenstein Law Group Comments on Testimony in Ongoing Robot Trial
6. Rottenstein Law Group Notes Medical Journal Article Advising Doctors To Use Caution When Prescribing Zithromax and Other Antibiotics
7. NuvaRing Lawsuit News: Rottenstein Law Group Responds to Judge’s Refusal to Dismiss Punitive Damages Claims
8. Lipitor Lawsuit News: Rottenstein Law Group Comments on FDA Approval of New Drug With Lipitor Compound
9. DePuy ASR Lawsuit Update: Rottenstein Law Group Comments on Delay of Second Federal Trial
10. Lipitor Lawsuit News: US Spending on Drugs Fell For First Time in 2012, Notes Rottenstein Law Group LLP
11. Da Vinci Surgical Robot Lawsuit News: Robot Maker Says Device Could Cause Internal Burns, Notes Rottenstein Law Group LLP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2016)... ... February 14, 2016 , ... ... of Heart Failure Nurses (AAHFN) is promoting healthier living with heart failure by ... of Life! Healthy Living with Heart Failure will kick-off February 14 and includes ...
(Date:2/13/2016)... ... February 13, 2016 , ... ... Voices of Recovery, the leading national organization representing the growing community of recovering ... public office to include Family Recovery in policies addressing addiction. , Although ...
(Date:2/13/2016)... ... February 13, 2016 , ... In ... states that vein visualization technology should be used to ensure patient safety when ... world, the INS Standards mandate the use of vein visualization technology in patients ...
(Date:2/13/2016)... ... , ... DDi , a Makro company, makes it ... expertise in eClinical Solutions. DDi has built its solution competency with a unique ... clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by ...
(Date:2/12/2016)... WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH ... for low-resource settings. The partnership will recruit top students from U.S. universities ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Va. , Feb. 12, 2016   National ... Hoey , RPh, MBA issued the following statement today ... released by the Centers for Medicare & ... raised by NCPA, beneficiary advocates and others: ... raised. We are still reviewing the full CMS analysis. ...
(Date:2/12/2016)... , Feb. 12, 2016 Hypermarcas ... a cash tender offer (the "Tender Offer") to ... outstanding aggregate principal amount of its 6.500% Senior ... ISIN Nos. US44915JAA88/ USP5246AAF05) (the "Notes"). In connection ... (the "Consent Solicitation") consents (the "Consents") of the ...
(Date:2/12/2016)... -- Innophos Holdings, Inc. (NASDAQ: IPHS ), a leading international ... it will host a live conference call on Tuesday, February ... quarter and full year 2015 results. ... quarter and full year results will be issued on Monday, ... --> --> The conference call can be ...
Breaking Medicine Technology: